KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses ...

Ashwin Kishtagari, MBBS, is Assistant Professor of Medicine in the division of hematology and oncology at Vanderbilt ...

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a ...

Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...

A novel epigenetic therapy has demonstrated activity against treatment-resistant acute myeloid leukaemia in preclinical ...

What Is Revuforj, and Why Does It Matter? Revuforj (revumenib) is an oral medicine approved for treating a type of cancer called acute myeloid leukemia (AML) that affects your bone marrow and blood.

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy ...

Preclinical study results suggest that targeting Hippo signaling may help address treatment resistance in acute myeloid ...

A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 ...

(RTTNews) - Shares of SELLAS Life Sciences Group Inc. (SLS) are up nearly 7% at $1.86 in premarket trading, following promising clinical data from its ongoing Phase 2 study of SLS009 in ...

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).